Richard E Champlin

List of Publications by Year in Descending Order

534 papers	14,243 citations	56 h-index	110 g-index
557 ext. papers	17,360 ext. citations	3.9 avg, IF	5.94 L-index

#	Paper	IF	Citations
534	Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability.. *JMIR Formative Research*, **2022**, 6, e29393	2.5	
533	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.. *Journal of Hematology and Oncology*, **2022**, 15, 12	22.4	0
532	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.. *Leukemia and Lymphoma*, **2022**, 1-9	1.9	2
531	Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. *Haematologica*, **2021**, 106, 1988-1990	6.6	6
530	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. *Blood*, **2021**, 138, 1802-1802	2.2	
529	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2021**, 138, 1779-1779	2.2	
528	A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. *Blood*, **2021**, 138, 3941-3941	2.2	
527	Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. *Blood*, **2021**, 138, 482-482	2.2	1
526	Impact of Vitamin D Deficiency on Survival for Patients Received Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT). *Blood*, **2021**, 138, 4853-4853	2.2	
525	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. *Leukemia and Lymphoma*, **2021**, 1-12	1.9	0
524	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). *Bone Marrow Transplantation*, **2021**,	4.4	5
523	Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. *Haematologica*, **2021**, 106, 269-274	6.6	1
522	Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2021**, 56, 1746-1749	4.4	2
521	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. *Transplantation and Cellular Therapy*, **2021**, 27, 272.e1-272.e5		3
520	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 243.e1-243.e6		0
519	High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. *Frontiers in Immunology*, **2021**, 12, 675679	8.4	10
518	Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. *Clinical Infectious Diseases*, **2021**, 73, 1346-1354	11.6	8

517	Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. *Bone Marrow Transplantation*, **2021**, 56, 2005-2012	4.4	1
516	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. *Cancer*, **2021**, 127, 2648-2656	6.4	8
515	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30 Malignancies. *Clinical Cancer Research*, **2021**, 27, 3744-3756	12.9	7
514	Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. *Frontiers in Immunology*, **2021**, 12, 631353	8.4	3
513	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. *Transplantation and Cellular Therapy*, **2021**, 27, 404.e1-404.e5		1
512	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. *Transplantation and Cellular Therapy*, **2021**, 27, 430.e1-430.e7		5
511	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. *Leukemia*, **2021**,	10.7	1
510	Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. *American Journal of Hematology*, **2021**, 96, E350-E353	7.1	1
509	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. *Blood*, **2021**, 138, 1733-1739	2.2	2
508	Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. *Cancer*, **2021**, 127, 3381-3389	6.4	2
507	Targeting the □v integrin/TGF-□axis improves natural killer cell function against glioblastoma stem cells. *Journal of Clinical Investigation*, **2021**, 131,	15.9	17
506	Generation of glucocorticoid-resistant SARS-CoV-2 T□cells for adoptive cell therapy. *Cell Reports*, **2021**, 36, 109432	10.6	8
505	Can we cure refractory Hodgkin's lymphoma with transplantation?. *Bone Marrow Transplantation*, **2021**, 56, 278-281	4.4	1
504	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. *Acta Haematologica*, **2021**, 144, 74-81	2.7	1
503	Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. *Bone Marrow Transplantation*, **2021**, 56, 745-748	4.4	2
502	Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. *Blood*, **2021**, 137, 624-636	2.2	60
501	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. *Cancer*, **2021**, 127, 1598-1605	6.4	3
500	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation **2021**, 9,		3

499	GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. *Frontiers in Immunology*, **2021**, 12, 626098	8.4	6
498	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. *Frontiers in Oncology*, **2021**, 11, 625707	5.3	5
497	Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking. *Cytotherapy*, **2021**, 23, 1029-1035	4.8	1
496	Decrease post-transplant relapse using donor-derived expanded NK-cells. *Leukemia*, **2021**,	10.7	7
495	CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. *Blood Advances*, **2021**, 5, 2799-2806	7.8	6
494	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. *Transplantation and Cellular Therapy*, **2021**, 27, 913.e1-913.e12		0
493	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. *Transplantation and Cellular Therapy*, **2021**, 27, 689-695		2
492	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. *Haematologica*, **2021**, 106, 3211-3214	6.6	3
491	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. *Transplantation and Cellular Therapy*, **2021**, 27, 642-649		4
490	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. *Journal of Clinical Oncology*, **2021**, 39, 2710-2719	2.2	9
489	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. *Clinical Cancer Research*, **2021**, 27, 5847-5856	12.9	0
488	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. *American Journal of Hematology*, **2021**, 96, E455-E457	7.1	0
487	Treatment of allosensitized patients receiving allogeneic transplantation. *Blood Advances*, **2021**, 5, 4031-4043	7.8	3
486	Mismatch in SIRP□, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. *Blood Advances*, **2021**, 5, 3407-3417	7.8	0
485	Cardiac Toxicity after Matched Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. *Blood Advances*, **2021**,	7.8	2
484	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. *Transplantation and Cellular Therapy*, **2021**, 27, 837.e1-837.e10		
483	Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. *Bone Marrow Transplantation*, **2021**, 56, 1316-1324	4.4	4
482	Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia.. *Blood*, **2021**,	2.2	6

481	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. *Blood Advances*, **2020**, 4, 2073-2083	7.8	21
480	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1439-1445	4.7	8
479	Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. *Blood*, **2020**, 136, 1786-1789	2.2	14
478	The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. *American Journal of Hematology*, **2020**, 95, 1127	7.1	2
477	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1247-1256	4.7	46
476	Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. *Transplant Infectious Disease*, **2020**, 22, e13395	2.7	
475	Haploidentical transplants for patients with graft failure after the first allograft. *American Journal of Hematology*, **2020**, 95, E267	7.1	1
474	Haploidentical transplants for patients with relapse after the first allograft. *American Journal of Hematology*, **2020**, 95, 1187	7.1	1
473	Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. *Annals of the American Thoracic Society*, **2020**, 17, 1329-1333	4.7	4
472	Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. *Cancer*, **2020**, 126, 2183-2192	6.4	8
471	Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies. *Clinical Cancer Research*, **2020**, 26, 2404-2410	12.9	5
470	Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. *Cancer*, **2020**, 126, 2193-2205	6.4	17
469	Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1013-1020	4.7	13
468	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. *New England Journal of Medicine*, **2020**, 382, 545-553	59.2	652
467	Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. *Blood*, **2020**, 136, 11-13	2.2	
466	Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial. *Blood*, **2020**, 136, 40-42	2.2	
465	PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. *Blood*, **2020**, 136, 6-7	2.2	
464	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). *Blood*, **2020** , 136, 17-18	2.2	

463	Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma. *Blood*, **2020**, 136, 9-11	2.2	
462	BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM). *Blood*, **2020**, 136, 40-41	2.2	
461	Immunologic Predictors for Clinical Responses in Patients with Myelodysplastic Syndromes Treated with Immune Checkpoint Blockade. *Blood*, **2020**, 136, 4-4	2.2	
460	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. *Blood*, **2020**, 136, 18-19	2.2	
459	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2020**, 136, 22-22	2.2	
458	Maintenance Treatment with Guadecitabine (SGI-110) in High Risk MDS and AML Patients after Allogeneic Stem Cell Transplantation. *Blood*, **2020**, 136, 29-30	2.2	0
457	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. *Blood*, **2020**, 136, 17-18	2.2	
456	A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab. *Blood*, **2020**, 136, 2-4	2.2	
455	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. *Blood*, **2020**, 136, 42-43	2.2	
454	Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. *Blood*, **2020**, 136, 39-41	2.2	
453	Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis. *Blood*, **2020**, 136, 1-1	2.2	
452	Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. *Blood*, **2020**, 136, 24-25	2.2	
451	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. *Blood*, **2020**, 136, 34-35	2.2	
450	Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia. *Blood*, **2020**, 136, 11-12	2.2	0
449	Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. *Blood*, **2020**, 136, 20-21	2.2	
448	Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. *Blood*, **2020**, 136, 10-12	2.2	
447	Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. *Blood*, **2020**, 136, 20-21	2.2	
446	Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. *Blood*, **2020**, 136, 10-11	2.2	

445	Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. *Blood*, **2020**, 136, 13-14	2.2	0
444	Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting. *Blood*, **2020**, 136, 10-11	2.2	
443	Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. *Blood*, **2020**, 136, 14-15	2.2	
442	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. *Blood*, **2020**, 136, 23-24	2.2	
441	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. *Blood*, **2020**, 136, 27-28	2.2	
440	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. *Blood*, **2020**, 136, 40-41	2.2	
439	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. *Blood*, **2020**, 136, 9-10	2.2	
438	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. *Blood*, **2020**, 136, 39-40	2.2	
437	A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine □ Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. *Blood*, **2020**, 136, 37-38	2.2	
436	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. *Blood*, **2020**, 136, 24-25	2.2	
435	Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission. *Blood*, **2020**, 136, 46-48	2.2	2
434	Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy **2020**,		2
433	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 665-671	4.7	7
432	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. *JAMA Oncology*, **2020**, 6, 486-493	13.4	19
431	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1077-1083	4.7	0
430	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. *Blood Advances*, **2020**, 4, 4834-4837	7.8	5
429	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. *Leukemia and Lymphoma*, **2020**, 61, 2811-2820	1.9	3
428	A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. *Blood Advances*, **2020**, 4, 5580-5588	7.8	42

427	Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. *Blood Advances*, **2020**, 4, 3474-3485	7.8	5
426	Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. *Blood Advances*, **2020**, 4, 3357-3367	7.8	13
425	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. *Lancet Haematology,the*, **2020**, 7, e523-e533	14.6	24
424	How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. *Blood*, **2020**, 136, 2741-2753	2.2	4
423	Overall survival in older patients with cancer. *BMJ Supportive and Palliative Care*, **2020**, 10, 25-35	2.2	12
422	Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. *Journal of Medical Virology*, **2020**, 92, 86-95	19.7	11
421	Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. *Blood*, **2020**, 135, 449-452	2.2	20
420	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. *Blood Advances*, **2020**, 4, 1296-1306	7.8	2
419	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. *Blood Advances*, **2020**, 4, 1038-1050	7.8	25
418	Next-Generation Sequencing of in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. *Frontiers in Oncology*, **2020**, 10, 582213	5.3	7
417	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. *American Journal of Hematology*, **2019**, 94, 1382-1387	7.1	14
416	HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. *Current Research in Translational Medicine*, **2019**, 67, 51-55	3.7	9
415	Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. *Acta Haematologica*, **2019**, 142, 176-184	2.7	2
414	Curative potential of hematopoietic stem cell transplantation for advanced psoriasis. *American Journal of Hematology*, **2019**, 94, E176-E180	7.1	4
413	Allogeneic Transplantation after Myeloablative Rituximab/BEAM ⍈ Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1347-1354	4.7	0
412	Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. *Haematologica*, **2019**, 104, e555-e557	6.6	3
411	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. *Lancet Haematology,the*, **2019**, 6, e266-e275	14.6	36
410	Hematologic malignancies and Li-Fraumeni syndrome. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	22

409	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1340-1346	4.7	3
408	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. *Leukemia and Lymphoma*, **2019**, 60, 442-452	1.9	11
407	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. *Leukemia and Lymphoma*, **2019**, 60, 3536-3543	1.9	7
406	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. *Annals of Hematology*, **2019**, 98, 2233-2235	3	4
405	Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls. *Blood*, **2019**, 134, 700-700	2.2	3
404	Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy.. *Journal of Clinical Oncology*, **2019**, 37, 7047-7047	2.2	1
403	Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with lymphoma and chronic lymphocytic leukemia (CLL) following targeted small molecules inhibitors (SMIs).. *Journal of Clinical Oncology*, **2019**, 37, 7550-7550	2.2	
402	Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. *Blood*, **2019**, 134, 3596-3596	2.2	
401	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. *Blood*, **2019**, 134, 257-257	2.2	0
400	Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. *Blood*, **2019**, 134, 4598-4598	2.2	
399	Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient. *Blood*, **2019**, 134, 1944-1944	2.2	
398	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. *Clinical Cancer Research*, **2019**, 25, 6781-6787	12.9	3
397	Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. *Blood Advances*, **2019**, 3, 2836-2844	7.8	24
396	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. *Blood Advances*, **2019**, 3, 1858-1867	7.8	13
395	A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. *Blood Advances*, **2019**, 3, 4117-4130	7.8	12
394	Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. *EBioMedicine*, **2019**, 39, 612-620	8.8	12
393	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1039-1044	4.7	9
392	Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. *Bone Marrow Transplantation*, **2019**, 54, 601-606	4.4	18

391	Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. *Bone Marrow Transplantation*, **2019**, 54, 1245-1253	4.4	6
390	Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 800-809	4.7	8
389	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. *American Journal of Hematology*, **2019**, 94, E2-E5	7.1	3
388	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 505-514	4.7	9
387	Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. *Bone Marrow Transplantation*, **2019**, 54, 839-848	4.4	18
386	Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. *American Journal of Hematology*, **2019**, 94, E72-E74	7.1	0
385	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. *Cancer*, **2018**, 124, 2134-2141	6.4	19
384	Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study. *Transplant International*, **2018**, 31, 639-648	3	10
383	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1602-1609	4.7	7
382	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. *Cancer*, **2018**, 124, 2534-2540	6.4	17
381	Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1514-1520	4.7	41
380	Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. *Blood*, **2018**, 131, 1248-1257	2.2	11
379	Stem Cell Transplantation for Treatment of Malignancy **2018**, 201-214		
378	Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34 Selected and Unmodified Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1079-1087	4.7	12
377	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. *Quality of Life Research*, **2018**, 27, 979-985	3.7	3
376	Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. *Archives of Osteoporosis*, **2018**, 13, 38	2.9	7
375	Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. *British Journal of Haematology*, **2018**, 183, 831-835	4.5	2
374	Neurocognitive deficits in older patients with cancer. *Journal of Geriatric Oncology*, **2018**, 9, 482-487	3.6	14

373	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. *Leukemia and Lymphoma*, **2018**, 59, 515-518	1.9	3
372	Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, e41-e50	2	10
371	Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 353-358	4.7	33
370	Risk factors for falls in older patients with cancer. *BMJ Supportive and Palliative Care*, **2018**, 8, 34-37	2.2	18
369	Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. *Journal of Geriatric Oncology*, **2018**, 9, 81-83	3.6	8
368	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. *JAMA Oncology*, **2018**, 4, 230-234	13.4	92
367	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1232-1236	4.7	36
366	CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 2017-2024	4.7	75
365	Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy. *Journal of Experimental and Clinical Cancer Research*, **2018**, 37, 150	12.8	1
364	Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation* , **2018**, 24, 2197-2203	4.7	18
363	Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. *Experimental Hematology*, **2018**, 67, 49-59.e1	3.1	4
362	Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. *Blood*, **2018**, 132, 971-971	2.2	20
361	Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. *Blood*, **2018**, 132, 553-553	2.2	13
360	Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. *Blood*, **2018**, 132, 1599-1599	2.2	1
359	Is a matched unrelated donor search needed for all allogeneic transplant candidates?. *Blood Advances*, **2018**, 2, 2254-2261	7.8	13
358	Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. *Oncotarget*, **2018**, 9, 35611-35622	3.3	13
357	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. *Blood*, **2018**, 132, 4607-4607	2.2	
356	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 726-733	4.7	45

355	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. *Lancet Haematology,the*, **2018**, 5, e532-e542	14.6	14
354	Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. *Frontiers in Immunology*, **2018**, 9, 2444	8.4	9
353	Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. *New England Journal of Medicine*, **2018**, 379, 1443-1451	59.2	87
352	Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. *Oncotarget*, **2018**, 9, 3908-3921	3.3	26
351	Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. *British Journal of Haematology*, **2018**, 183, 578-587	4.5	44
350	Stem cell transplantation outcomes in lymphoblastic lymphoma. *Leukemia and Lymphoma*, **2017**, 58, 366-371	4.7	8
349	Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. *Cancer*, **2017**, 123, 2025-2034	6.4	32
348	Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 581-587	4.7	12
347	Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. *Pediatric Transplantation*, **2017**, 21, e12890	1.8	2
346	Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. *Transfusion*, **2017**, 57, 1052-1057	2.9	6
345	Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation* , **2017**, 23, 1059-1063	4.7	1
344	The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. *Leukemia and Lymphoma*, **2017**, 58, 2705-2716	1.9	5
343	Hematopoietic Cell Transplantation **2017**, 1-13		1
342	A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. *British Journal of Haematology*, **2017**, 178, 561-570	4.5	6
341	Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1359-1366	4.7	16
340	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. *Cancer*, **2017**, 123, 3568-3575	6.4	8
339	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. *Lancet Haematology,the*, **2017**, 4, e283-e292	14.6	13
338	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. *Cancer*, **2017**, 123, 2661-2670	6.4	8

337	Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. *British Journal of Haematology*, **2017**, 177, 567-577	4.5	5
336	Prognostic Index for Critically Ill Allogeneic Transplantation Patients. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 991-996	4.7	10
335	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. *British Journal of Haematology*, **2017**, 177, 457-466	4.5	100
334	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. *American Journal of Hematology*, **2017**, 92, 331-337	7.1	29
333	Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. *Haematologica*, **2017**, 102, 110-117	6.6	38
332	A subset of virus-specific CD161 T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. *Blood*, **2017**, 129, 740-758	2.2	16
331	Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. *Frontiers in Immunology*, **2017**, 8, 1937	8.4	14
330	Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. *Blood*, **2017**, 130, 1857-1868	2.2	164
329	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. *European Journal of Haematology*, **2017**, 99, 532-535	3.8	16
328	Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 901-923	5.5	46
327	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 318-324	4.7	44
326	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 285-292	4.7	16
325	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. *Cancer*, **2017**, 123, 294-302	6.4	61
324	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. *Cancer*, **2017**, 123, 459-467	6.4	39
323	Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. *Transplant Infectious Disease*, **2017**, 19, e12632	2.7	16
322	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. *European Journal of Haematology*, **2017**, 98, 263-268	3.8	3
321	Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 2166-2171	4.7	19
320	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 47-53	4.7	39

319	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. *Leukemia and Lymphoma*, **2016**, 57, 1607-15	1.9	13
318	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. *American Journal of Hematology*, **2016**, 91, E442-7	7.1	14
317	Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. *Cancer*, **2016**, 122, 3316-3326	6.4	62
316	Hematopoietic stem cell transplantation **2016**, 440-451		1
315	Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E7788-E7797	11.5	213
314	Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. *Molecular Imaging and Biology*, **2016**, 18, 838-848	3.8	21
313	Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. *Experimental Hematology*, **2016**, 44, 458-65	3.1	5
312	Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. *Leukemia Research*, **2016**, 47, 100-8	2.7	3
311	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. *British Journal of Haematology*, **2016**, 172, 392-400	4.5	79
310	Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	37
309	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 961-5	4.7	11
308	Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. *Leukemia and Lymphoma*, **2016**, 57, 2644-52	1.9	5
307	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 432-40	4.7	95
306	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 36-42	2	4
305	Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 717-722	4.7	42
304	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 48-56	21.7	141
303	Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 505-13	4.7	19
302	Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 226-231	4.7	11

301	Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 493-8	4.7	31
300	Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. *Blood*, **2016**, 128, 2916-2916	2.2	1
299	Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. *Blood*, **2016**, 128, 3554-3554	2.2	2
298	Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2016**, 128, 5884-5884	2.2	1
297	Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. *Oncotarget*, **2016**, 7, 63829-63838	3.3	12
296	Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial. *BoneKEy Reports*, **2016**, 5, 843		3
295	Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. *Blood*, **2016**, 128, 2270-2270	2.2	
294	Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2016**, 128, 2276-2276	2.2	
293	Allogeneic Stem Cell Transplantation Versus Medical Therapy in Patients with Advanced Myelofibrosis: Matched Survival Analysis and the Effect of JAK2 Inhibitor Therapy. *Blood*, **2016**, 128, 4687-4687	2.2	
292	Haploidentical Donors in Addition to Transplantation in Chronic Phase Associate with Improved Gvhd-Free Relapse-Free Survival (GRFS) for Patients with Advanced CML. *Blood*, **2016**, 128, 4583-4583	2.2	
291	Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. *PLoS ONE*, **2016**, 11, e0159477	3.7	41
290	Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. *British Journal of Haematology* , **2016**, 173, 444-55	4.5	41
289	Long-Term Outcomes after Treatment with Clofarabine + Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1792-1800	4.7	9
288	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. *Cancer*, **2016**, 122, 2680-8	6.4	31
287	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. *European Journal of Haematology*, **2016**, 97, 342-7	3.8	7
286	KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. *Blood*, **2016**, 128, 2819-2823	2.2	19
285	Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application. *Scientific Reports*, **2016**, 6, 21757	4.9	24
284	Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1218-1226	4.7	42

283	Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1333-1337	4.7	18
282	Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1290-1298	4.7	81
281	The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. *Blood*, **2016**, 127, 260-7	2.2	158
280	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. *Blood*, **2016**, 127, 1656-65	2.2	184
279	IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. *Blood*, **2016**, 128, 1346-61	2.2	56
278	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. *Blood*, **2016**, 128, 297-312	2.2	40
277	Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 2159-2164	4.7	15
276	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. *Cancer*, **2016**, 122, 3831-3837	6.4	20
275	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. *Cancer*, **2016**, 122, 3812-3820	6.4	11
274	Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. *Experimental Hematology*, **2015**, 43, 448-61.e2	3.1	13
273	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1914-20	4.7	32
272	Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1948-54	4.7	44
271	Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1714-20	4.7	26
270	Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1392-8	4.7	101
269	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. *Journal of Clinical Oncology*, **2015**, 33, 4167-75	2.2	111
268	Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1863-1869	4.7	253
267	Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 687-93	2	21
266	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. *Cancer Research*, **2015**, 75, 3505-18	10.1	246

265	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1413-7	4.7	4
264	Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1529-1531	4.7	4
263	Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. *Biology of Blood and Marrow Transplantation*, **2015** , 21, 55-9	4.7	26
262	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. *Blood*, **2015**, 126, 1033-40	2.2	431
261	Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System. *Journal of Visualized Experiments*, **2015**,	1.6	13
260	Better allele-level matching improves transplant-related mortality after double cord blood transplantation. *Haematologica*, **2015**, 100, 1361-70	6.6	27
259	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. *American Journal of Hematology*, **2015**, 90, 1065-70	7.1	16
258	Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Cancer*, **2015**, 121, 4158-64	6.4	129
257	Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. *PLoS ONE*, **2015**, 10, e0128151	3.7	36
256	Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. *Bone Marrow Transplantation*, **2015**, 50, 939-946	4.4	25
255	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 1405-1412	4.7	20
254	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 906-12	4.7	26
253	Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. *Journal of Clinical Oncology*, **2015**, 33, 364-9	2.2	41
252	Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?. *Biology of Blood and Marrow Transplantation*, **2015**, 21, 713-9	4.7	26
251	Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. *Blood*, **2015**, 126, 3155-3155	2.2	5
250	Ibrutinib Treatment Modulates T Cell Activation and Polarization in Immune Response. *Blood*, **2015**, 126, 3435-3435	2.2	7
249	Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2015**, 126, 4321-4321	2.2	2
248	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. *Blood*, **2015**, 126, 854-854	2.2	5

247	Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. *Oncotarget*, **2015**, 6, 30487-99	3.3	28
246	Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. *New England Journal of Medicine*, **2014**, 370, 1781-9	59.2	253
245	Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1975-81	4.7	167
244	Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. *Journal of Clinical Oncology*, **2014**, 32, 3497-505	2.2	175
243	Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1687-95	4.7	9
242	Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10660-5	11.5	130
241	Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1767-71	4.7	28
240	Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1618-25	4.7	33
239	Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. *Clinical Cancer Research*, **2014**, 20, 5708-19	12.9	82
238	Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1262-73	4.7	130
237	The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 319-26	2	45
236	Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. *Journal of Geriatric Oncology*, **2014**, 5, 422-30	3.6	49
235	The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, e1-5	2	18
234	Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. *Blood*, **2014**, 123, 3263-8	2.2	86
233	Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1139-44	4.7	18
232	Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. *Cytotherapy*, **2014**, 16, 84-9	4.8	32
231	Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).. *Journal of Clinical Oncology*, **2014**, 32, 4517-4517	2.2	
230	Factors associated with bone fractures following hematopoietic stem cell transplantation.. *Journal of Clinical Oncology*, **2014**, 32, 9600-9600	2.2	

229	Autologous stem cell transplantation in dialysis-dependent myeloma patients.. *Journal of Clinical Oncology*, **2014**, 32, 8601-8601	2.2	
228	Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.. *Journal of Clinical Oncology*, **2014**, 32, 8538-8538	2.2	
227	Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. *Best Practice and Research in Clinical Haematology*, **2013**, 26, 297-300	4.2	19
226	Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1059-64	4.7	46
225	A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 1453-8	4.7	15
224	Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 180-4	4.7	42
223	Fifty years of melphalan use in hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 344-56	4.7	62
222	Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 1872-80	5.1	105
221	Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. *PLoS ONE*, **2013**, 8, e76781	3.7	119
220	First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. *Blood*, **2013**, 122, 166-166	2.2	10
219	Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. *Blood*, **2013**, 122, 305-305	2.2	1
218	Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). *Blood*, **2013**, 122, 410-410	2.2	5
217	Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. *Blood*, **2013**, 122, 5356-5356	2.2	5
216	Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2013**, 31, 7010-7010	2.2	
215	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). *Blood*, **2013**, 122, 2142-2142	2.2	
214	Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. *Blood*, **2013**, 122, 3358-3358	2.2	
213	Phosphorylation Of GSK3 Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells. *Blood*, **2013**, 122, 2551-2551	2.2	
212	Is There An Expiration Date For Cord Blood Units In Storage?. *Blood*, **2013**, 122, 299-299	2.2	

211	Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation. *Blood*, **2013**, 122, 2880-2880	2.2	
210	Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. *American Journal of Hematology*, **2012**, 87, 272-6	7.1	24
209	The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. *Blood*, **2012**, 119, 2738-45; quiz 2969	2.2	95
208	Cord-blood engraftment with ex vivo mesenchymal-cell coculture. *New England Journal of Medicine*, **2012**, 367, 2305-15	59.2	377
207	NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. *Immunotherapy*, **2012**, 4, 305-13	3.8	17
206	Progress in haploidentical stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2012**, 18, 372-80	4.7	33
205	Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. *Biology of Blood and Marrow Transplantation*, **2012**, 18, 584-92	4.7	62
204	Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2012**, 18, 1835-44	4.7	194
203	Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma. *Cancer Journal (Sudbury, Mass)*, **2012**, 18, 457-62	2.2	16
202	Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. *Leukemia and Lymphoma*, **2012**, 53, 1525-9	1.9	22
201	EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.. *Blood*, **2012**, 120, 3094-3094	2.2	1
200	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. *Blood*, **2012**, 120, 4200-4200	2.2	4
199	Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. *PLoS ONE*, **2012**, 7, e30264	3.7	360
198	Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. *Blood*, **2012**, 120, 3115-3115	2.2	
197	Reconstitution of Lymphocyte Subsets and Outcomes After Matched and Mismatched Hematopoietic Stem-Cell Transplantation. *Blood*, **2012**, 120, 4485-4485	2.2	
196	Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.. *Blood*, **2012**, 120, 3129-3129	2.2	
195	Relevance and Factors Predicting for Early Lymphocyte Recovery After Allogeneic Bone Marrow Stem Cell Transplantation (BMT).. *Blood*, **2012**, 120, 3053-3053	2.2	
194	Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience. *Blood*, **2012**, 120, 1977-1977	2.2	

193	Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11 Suppl 1, S96-100	2	3
192	Clofarabine fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 893-900	4.7	76
191	Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 1723-4	4.7	8
190	Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. *Blood*, **2011**, 118, 5957-64	2.2	146
189	The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. *Biochemical Pharmacology*, **2011**, 81, 222-32	6	37
188	Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. *Blood*, **2011**, 118, 1794-1794	2.2	2
187	CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. *Blood*, **2011**, 118, 246-246	2.2	1
186	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. *Blood*, **2011**, 118, 333-333	2.2	1
185	Targeting Leukemias by CD123 Specific Chimeric Antigen Receptor. *Blood*, **2011**, 118, 1908-1908	2.2	
184	12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years,. *Blood*, **2011**, 118, 4138-4138	2.2	
183	Prediction of Apheresis Peripheral Blood Stem Cell Yield Based on Pre Apheresis Absolute Peripheral Blood Stem Cell Counts,. *Blood*, **2011**, 118, 4047-4047	2.2	
182	Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. *Blood*, **2011**, 118, 3106-3106	2.2	
181	Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. *Blood*, **2011**, 118, 894-894	2.2	
180	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. *Blood*, **2011**, 118, 2006-2006	2.2	
179	Increased Bone Marrow Plasma Cell Infiltration Pre-Transplant Is Associated with Worse Outcomes in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma,. *Blood*, **2011**, 118, 4135-4135	2.2	
178	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,. *Blood*, **2011**, 118, 4118-4118	2.2	3
177	Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. *Cancer*, **2010**, 116, 5420-31	6.4	334
176	5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. *Leukemia Research*, **2010**, 34, 364-72	2.7	37

175	Impact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignanciesimpact of In Vivo T-Cell Depletion on Outcome of Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies. *Blood*, **2010**, 116, 2305-2305	2.2	1
174	A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation. *Blood*, **2010**, 116, 2358-2358	2.2	2
173	NK Cell Proliferation and Cytolytic Function Are Compromised In the Hypoxic Tumor Microenvironment. *Blood*, **2010**, 116, 4291-4291	2.2	3
172	Reduced Intensity Conditioning (RIC) Transplantation In Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes. *Blood*, **2010**, 116, 908-908	2.2	1
171	Human-Leukocyte-Histocompatibility Antigens Predict Response to Rituximab and Donor Lymphocyte Infusion (DLI) After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL). *Blood*, **2010**, 116, 2548-2548	2.2	
170	Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. *Blood*, **2010**, 116, 3510-3510	2.2	
169	Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma.. *Blood*, **2010**, 116, 4569-4569	2.2	
168	Novel Influenza A (2009/H1N1) Infection In Patients with Hematological Malignancies During the 2009 Pandemic Outbreak: Early Antiviral Treatment Improves Survival. *Blood*, **2010**, 116, 1731-1731	2.2	1
167	Impact of FLT3-ITD Allelic Ratio In Treatment of Acute Myelogenous Leukemia Including Allogeneic Stem Cell Transplant. *Blood*, **2010**, 116, 1722-1722	2.2	1
166	Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS.. *Blood*, **2010**, 116, 3446-3446	2.2	
165	Leuprolide Acetate (GnRH Agonist) to Enhance Immune Function Post-Autologous Hematopoietic Stem Cell Transplantation (HSCT). *Blood*, **2010**, 116, 4292-4292	2.2	
164	Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model. *Blood*, **2010**, 116, 2453-2453	2.2	
163	Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. *Blood*, **2010**, 116, 2100-2100	2.2	
162	Effect of Stem Cell Source From Unrelated Donors on Transplant Outcomes In Severe Aplastic Anemia (SAA): a Comparison of Unrelated Bone Marrow (BM) and Peripheral Blood Progenitor Cells (PBPC). *Blood*, **2010**, 116, 531-531	2.2	
161	Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older.. *Blood*, **2010**, 116, 4576-4576	2.2	
160	Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. *Blood*, **2010**, 116, 2341-2341	2.2	
159	Poor FEV1 or DLco on Pre-Transplant PFT Does Not Compromise Outcomes In Patients Undergoing a Reduced-Intensity Allogeneic Progenitor Cell Transplant.. *Blood*, **2010**, 116, 1322-1322	2.2	
158	Alloreactive Nk Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study. *Blood*, **2010**, 116, 489-489	2.2	

157	Concordance Between the Serum Levels of Interleukin-6, Microrna-21, and the Severity of Subjective Symptoms of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. *Blood*, **2010**, 116, 2953-2953	2.2	
156	Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. *Cancer*, **2009**, 115, 1899-905	6.4	166
155	Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. *International Journal of Hematology*, **2009**, 90, 627-634	2.3	2
154	Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. *Biology of Blood and Marrow Transplantation*, **2009**, 15, 1265-70	4.7	27
153	A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. *Biology of Blood and Marrow Transplantation*, **2009**, 15, 1555-62	4.7	80
152	Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. *Clinical Lymphoma and Myeloma*, **2009**, 9 Suppl 3, S261-5		10
151	High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. *Transplantation*, **2009**, 88, 1019-24	1.8	178
150	Response: MHC class I chain□elated gene A (MICA) in unrelated donor transplantation. *Blood*, **2009**, 114, 4754-4755	2.2	5
149	Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2009**, 114, 2287-2287	2.2	1
148	IL-7 as a Membrane-Bound Molecule for the Costimulation of Tumor-Specific T Cells.. *Blood*, **2009**, 114, 3035-3035	2.2	2
147	Third Generation Chimeric Antigen Receptors Containing CD137 or CD134 Signaling Endodomains Augment CD19-Specific T-Cell Effector Function.. *Blood*, **2009**, 114, 4097-4097	2.2	1
146	Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.. *Blood*, **2009**, 114, 868-868	2.2	1
145	Enrichment of Mononuclear Cells From Cryopreserved Cord Blood Units Using the Purecell□Select System.. *Blood*, **2009**, 114, 2159-2159	2.2	
144	Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).. *Blood*, **2009**, 114, 2310-2310	2.2	0
143	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).. *Blood*, **2009**, 114, 3213-3213	2.2	
142	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.. *Blood*, **2009**, 114, 2309-2309	2.2	
141	Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation.. *Blood*, **2009**, 114, 4354-4354	2.2	
140	Sustained Ex Vivo Expansion of Human Peripheral Blood NK Cells Using Artificial APCs Bearing Membrane-Bound IL-21.. *Blood*, **2009**, 114, 3030-3030	2.2	

139	Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma.. *Blood*, **2009**, 114, 1227-1227	2.2	
138	Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 672-84	4.7	136
137	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. *Blood*, **2008**, 111, 5530-6	2.2	261
136	Altered gene expression in busulfan-resistant human myeloid leukemia. *Leukemia Research*, **2008**, 32, 1684-97	2.7	43
135	Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission.. *Blood*, **2008**, 112, 1141-1141	2.2	1
134	Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). *Blood*, **2008**, 112, 2931-2931	2.2	2
133	Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations. *Blood*, **2008**, 112, 3302-3302	2.2	1
132	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. *Blood*, **2008**, 112, 3320-3320	2.2	1
131	Impact of Pretransplant Cytogenetics and Marrow Remission Status on Outcome of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation Conditioned with Busulfan and Fludarabine. *Blood*, **2008**, 112, 341-341	2.2	1
130	Outcomes in Patients with Chronic Myelomonocytic Leukemia: Analysis of 279 Patients.. *Blood*, **2008**, 112, 3235-3235	2.2	
129	Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.. *Blood*, **2008**, 112, 1128-1128	2.2	
128	Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.. *Blood*, **2008**, 112, 1142-1142	2.2	
127	High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma. *Blood*, **2008**, 112, 4452-4452	2.2	
126	Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. *Blood*, **2008**, 112, 3298-3298	2.2	
125	Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS. *Blood* , **2008**, 112, 2999-2999	2.2	1
124	T Cells Demonstrate Enhanced Specificity for CD19+ Malignancies When Stimulated with IL-21.. *Blood*, **2008**, 112, 1539-1539	2.2	
123	Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post- Transplant Outcomes in Patients with AML. *Blood*, **2008**, 112, 3000-3000	2.2	
122	Treatment of AML in First Remission (CR1) with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Unrelated Donors (UD).. *Blood*, **2008**, 112, 976-976	2.2	

121	Stem Cell Transplant (SCT) for Patients (pts) with Chronic Myeloid Leukemia (CML) Resistant to Tyrosine Kinase Inhibitors (TKI) with BCR-ABL Kinase Domain (KD) Mutation T315I.. *Blood*, **2008**, 112, 2120-2120	2.2	
120	Upregulation of XAF1 by 5-Aza-2?-Deoxycytidine Sensitizes Busulfan-Resistant Human CML Cells; Implications for Pretransplant Conditioning Therapy in Myeloid Leukemia. *Blood*, **2008**, 112, 5046-5046	2.2	
119	Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) from Donors Other Than Matched Siblings: A Prospective Evaluation of Hemorrhagic Cystitis (HC) Incidence. *Blood*, **2008**, 112, 50-50	2.2	1
118	Donor-Recipient Mismatches in MHC Class I Chain-Related Gene a (MICA) in Unrelated Donor (UD) Transplantation. *Blood*, **2008**, 112, 58-58	2.2	
117	Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia. *Blood*, **2008**, 112, 2905-2905	2.2	
116	Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. *Blood*, **2008**, 112, 3306-3306	2.2	
115	Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS.. *Blood*, **2008**, 112, 2227-2227	2.2	
114	Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). *Blood*, **2008**, 112, 4326-4326	2.2	
113	Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. *Blood*, **2008**, 112, 3297-3297	2.2	
112	Regulatory and Nai ve T Cells in Unmanipulated Donor Grafts Are Not Associated with Acute Graft Vs Host Disease in Matched Sibling Transplants for AML. *Blood*, **2008**, 112, 719-719	2.2	
111	Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. *Blood*, **2008**, 112, 799-799	2.2	
110	Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 56-64	4.7	95
109	Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 454-62	4.7	100
108	PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia.. *Blood*, **2007**, 110, 283-283	2.2	6
107	Sustained Engraftment Using Fludarabine, Melphalan and Thiotepa Conditioning for Haploidentical Stem Cell Transplantation.. *Blood*, **2007**, 110, 5081-5081	2.2	2
106	PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival.. *Blood*, **2007**, 110, 577-577	2.2	5
105	Zevalin /BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. *Blood*, **2007**, 110, 620-620	2.2	5
104	Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).. *Blood*, **2007**, 110, 948-948	2.2	2

103	Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.. *Blood*, **2007**, 110, 5126-5126	2.2	
102	Non-Integrating Gene Transfer To Redirect Specificity of Lymphocytes towards Pediatric CD19+ Malignancies. *Blood*, **2007**, 110, 3739-3739	2.2	
101	Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin's Lymphomas (NHLs).. *Blood*, **2007**, 110, 1900-1900	2.2	
100	A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.. *Blood*, **2007**, 110, 3032-3032	2.2	1
99	Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes.. *Blood*, **2007**, 110, 2977-2977	2.2	
98	Tacrolimus and Short-Term Methotrexate (mini-MTX) for Graft Versus Host Disease (GVHD) Prophylaxis after Unrelated Single Unit Cord Blood Transplant (CBT) in Pediatric Patients.. *Blood*, **2007**, 110, 5018-5018	2.2	
97	Mismatches in Low Expression HLA Class II Loci and MIC-A in Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT).. *Blood*, **2007**, 110, 3050-3050	2.2	
96	A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants.. *Blood*, **2007**, 110, 3051-3051	2.2	
95	Anti-Apoptotic Proteins, HSP90 and Activated STAT3 Contribute to Busulfan Resistance of Myeloid Leukemia Cells.. *Blood*, **2007**, 110, 3472-3472	2.2	1
94	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. *Blood*, **2007**, 110, 48-48	2.2	
93	Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation.. *Blood*, **2007**, 110, 3002-3002	2.2	
92	CD19-Specific T Cells for Treatment of Pediatric Acute Lymphocytic Leukemia Using Sleeping Beauty Transposition.. *Blood*, **2007**, 110, 2820-2820	2.2	
91	Jak2 Regulates Lyn Tyrosine Kinase through Interference with the SET/PP2A/Shp1 Pathway and Inhibition of Jak2 Induced Apoptosis in BCR-ABL+ Imatinib-Sensitive and Resistant CML Cells.. *Blood*, **2007**, 110, 3342-3342	2.2	
90	Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).. *Blood* , **2007**, 110, 5015-5015	2.2	
89	Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.. *Blood*, **2007**, 110, 329-329	2.2	1
88	Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. *Medicine (United States)*, **2006**, 85, 278-287	1.8	261
87	Hepatosplenic T-Cell Lymphoma: Clinical Characteristics and Treatment Outcome.. *Blood*, **2006**, 108, 2460-2460	2.2	3
86	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. *Blood*, **2006**, 108, 3090-3090	2.2	1

85	Two-Year Follow-Up Results at the M.D. Anderson Hospital with Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine-Melphalan as Preparative Regimen in Relapsed/Refractory Hodgkin's Lymphoma: Comparable Outcome with Matched Related and Unrelated Donors.. *Blood*, **2006**, 108, 3115-3115	2.2	1
84	Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized by Thymic Regeneration Failure.. *Blood*, **2006**, 108, 312-312	2.2	4
83	HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT).. *Blood*, **2006**, 108, 3125-3125	2.2	1
82	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's Lymphoma (NHL).. *Blood*, **2006**, 108, 315-315	2.2	11
81	Characterization of optimal T Cell/Dendritic Cell (DC) Co-Culture Conditions for Ex Vivo Expansion of Antigen-Specific Human T Cells.. *Blood*, **2006**, 108, 3654-3654	2.2	2
80	Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.. *Blood*, **2006**, 108, 3668-3668	2.2	4
79	The Role of Dasatinib in Patients with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Relapsing after Stem Cell Transplantation (SCT).. *Blood*, **2006**, 108, 4520-4520	2.2	5
78	Massive Mobilization of AML Cells into Circulation by Disruption of Leukemia/Stroma Cell Interactions Using CXCR4 Antagonist AMD3100: First Evidence in Patients and Potential for Abolishing Bone Marrow Microenvironment-Mediated Resistance.. *Blood*, **2006**, 108, 568-568	2.2	12
77	Chronic Graft-Versus-Host (cGVHD) after Non-Myeloablative Stem Cell Transplantation (NST) with Rituximab-Containing Conditioning Regimens for Non-Hodgkin's Lymphoma.. *Blood*, **2006**, 108, 5316-5316	2.2	
76	High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin's Lymphoma (NHL) in Patients over 65 Years of Age.. *Blood*, **2006**, 108, 3059-3059	2.2	
75	Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma.. *Blood*, **2006**, 108, 5422-5422	2.2	
74	ZAP-70 Status Does Not Predict Outcome after Nonmyeloablative Allogeneic Stem-Cell Transplantation (NST) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) That Fails To Respond to Conventional Chemoimmunotherapy.. *Blood*, **2006**, 108, 3028-3028	2.2	
73	In Utero Is Superior to Ex Utero Cord Blood Collection.. *Blood*, **2006**, 108, 3645-3645	2.2	
72	Does Polyoma (BK) Virus Contribute to Development of Hemorrhagic Cystitis (HC) in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation (UD HSCT) Recipients? A Prospective Evaluation.. *Blood*, **2006**, 108, 5282-5282	2.2	
71	Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.. *Blood*, **2006**, 108, 3101-3101	2.2	
70	Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. *Journal of Clinical Oncology*, **2005**, 23, 2240-7	2.2	115
69	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A New Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. *Blood*, **2005**, 106, 1159-1159	2.2	3
68	Prospective Feasibility Analysis of Reduced Intensity Conditioning Regimens (RIC) for Hematopoietic Stem Cell Transplantation (HSCT) in Elderly Patients with AML and MDS.. *Blood*, **2005**, 106, 2892-2892	2.2	2

67	RhG-CSF Mobilized and Apheresis-Collected Endothelial Progenitor Cells for Therapeutic Vasculogenesis.. *Blood*, **2005**, 106, 298-298	2.2	1
66	Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.. *Blood*, **2005**, 106, 44-44	2.2	3
65	Disruption of Leukemia/Stroma Cell Interactions by CXCR4 Antagonist AMD3465 Enhances Chemotherapy-Induced Apoptosis in AML.. *Blood*, **2005**, 106, 474-474	2.2	6
64	Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL).. *Blood*, **2005**, 106, 48-48	2.2	8
63	Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation.. *Blood*, **2005**, 106, 660-660	2.2	2
62	Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200 mg/M2 (MEL200).. *Blood*, **2005**, 106, 1177-1177	2.2	
61	The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2005**, 106, 1803-1803	2.2	
60	Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma (MM).. *Blood*, **2005**, 106, 2923-2923	2.2	
59	The Clinical Spectrum of Acute GVHD: Beyond Day 100.. *Blood*, **2005**, 106, 5377-5377	2.2	
58	Cell-Autonomous Upregulation of Dendritic Cell Immunocompetence Is Antigen-Dependent.. *Blood*, **2005**, 106, 2230-2230	2.2	
57	Secondary Malignancy after Allogeneic Stem Cell Transplantation: Incidence and Risk Factors.. *Blood*, **2005**, 106, 1123-1123	2.2	
56	Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).. *Blood*, **2005**, 106, 1135-1135	2.2	
55	Treatment of Graft Failure with Fludarabine (Flu), Antithymocyte Globulin (ATG) and a Second Allogeneic Stem Cell Transplantation (SCT).. *Blood*, **2005**, 106, 2734-2734	2.2	
54	Superior Acute Myeloid Leukemia-Specific T Cell Responses Using Dendritic Cells Pulsed with Apoptotic Bodies, vs.Tumor Lysates or mRNA.. *Blood*, **2005**, 106, 295-295	2.2	
53	Distribution and Differentiation of Donor-Derived Bone Marrow Stem Cells in Various Areas of the Human Brain.. *Blood*, **2005**, 106, 1685-1685	2.2	
52	Campath-IH Combined with Fludarabine/Cyclophophamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation.. *Blood*, **2005**, 106, 2902-2902	2.2	
51	Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens.. *Blood*, **2005**, 106, 2019-2019	2.2	
50	Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. *Blood*, **2004**, 104, 865-72	2.2	320

49	Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. *Blood*, **2004**, 104, 857-64	2.2	358
48	Results of Bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD.. *Blood*, **2004**, 104, 1651-1651	2.2	3
47	Immunotherapy with Donor Leukocyte Infusions (DLIS) in Relapsed Hodgkin Disease (HD) Following Allogeneic Stem Cell Transplantation (ALLO-SCT): CD3+ Cell Dose, GVHD and Disease Response.. *Blood*, **2004**, 104, 1654-1654	2.2	1
46	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.. *Blood*, **2004**, 104, 2301-2301	2.2	2
45	Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia.. *Blood*, **2004**, 104, 259-259	2.2	41
44	Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. *Blood*, **2004**, 104, 2738-2738	2.2	5
43	Targeted Radiotherapy to the Skeleton Using 166Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.. *Blood*, **2004**, 104, 5239-5239	2.2	1
42	Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.. *Blood*, **2004**, 104, 734-734	2.2	1
41	Sequential Treatment with Reduced Intensity Allogeneic Stem Cell Transplantation and Imatinib for Chronic Myelogenous Leukemia (CML.. *Blood*, **2004**, 104, 812-812	2.2	2
40	IV Busulfan (Bu) with Fludarabine (Flu) or Cyclophosphamide (Cy) - Comparing Ablative Conditioning Regimens for Allogeneic Transplantation in AML/MDS.. *Blood*, **2004**, 104, 97-97	2.2	3
39	Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H.. *Blood*, **2004**, 104, 5132-5132	2.2	
38	A Model to Predict Risk for Late Cytomegalovirus Reactivation after Allogeneic Stem Cell Transplantation for Hematological Malignancies.. *Blood*, **2004**, 104, 2241-2241	2.2	
37	Double Loading of Dendritic Cell MHC Class I and MHC Class II with an AML Antigen Repertoire Enhances Primary and Secondary T-Cell Responses In Vitro.. *Blood*, **2004**, 104, 2529-2529	2.2	1
36	Prevalence of Microbially Contaminated Hematopoietic Stem Cell Products.. *Blood*, **2004**, 104, 2228-2228	2.2	
35	Acute Myeloid Leukemia Lysate Loaded Dendritic Cells Exhibit Significant Phagocytic Function and Elicit Antigen-Specific Immune Response.. *Blood*, **2004**, 104, 2527-2527	2.2	
34	Reduced-Intensity Conditioning Regimen with BEAM/Rituximab for Patients with Refractory Non-Hodgkin Lymphomas.. *Blood*, **2004**, 104, 2315-2315	2.2	
33	Impact of Prior Pregnancy on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation.. *Blood*, **2004**, 104, 1638-1638	2.2	
32	Allogeneic Stem Cell Transplantation with Reduced-Intensity, Fludarabine-Based Conditioning in Relapsed and Refractory Hodgkin Disease: Low Transplant-Related Mortality and Impact of Intensity of Conditioning Regimen on Survival.. *Blood*, **2004**, 104, 2135-2135	2.2	

31	Effect of High-Dose Rituximab on Peripheral Blood Stem Cell Mobilization in Intermediate Grade Non-Hodgkin Lymphomas.. *Blood*, **2004**, 104, 2877-2877	2.2	
30	Retroviral Gene Transfer with Triple Genetic Reporter Genes into Human Cord Blood CD133+ Cells.. *Blood*, **2004**, 104, 5260-5260	2.2	
29	A Pilot Study for Haploidentical Transplant Using a Chemotherapy only Preparative Regimen eith T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts).. *Blood*, **2004**, 104, 5184-5184	2.2	
28	High Efficiency Transduction of Human Mesenchymal Stem Cells Using Retroviral Gene Transfer with Triple Reporter Genes.. *Blood*, **2004**, 104, 4258-4258	2.2	
27	Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma.. *Blood*, **2004**, 104, 3329-3329	2.2	
26	Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. *Oncology*, **2003**, 17, 94-100; discussion 103-7	1.8	15
25	Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. *Biology of Blood and Marrow Transplantation*, **2002**, 8, 145-54	4.7	164
24	Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. *Blood*, **2001**, 97, 631-7	2.2	508
23	Impact of high-dose chemotherapy on peripheral T-cell lymphomas. *Journal of Clinical Oncology*, **2001**, 19, 3766-70	2.2	131
22	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. *American Journal of Hematology*, **2001**, 67, 227-33	7.1	18
21	A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. *British Journal of Haematology*, **2000**, 109, 770-2	4.5	40
20	Allogeneic haematopoietic transplantation for Richter's syndrome. *British Journal of Haematology*, **2000**, 110, 897-9	4.5	31
19	Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. *Nature Medicine*, **2000**, 6, 1018-23	50.5	581
18	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. *British Journal of Haematology*, **2000**, 111, 18-29	4.5	1
17	Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. *Current Oncology Reports*, **2000**, 2, 132-9	6.3	19
16	Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens. *Current Oncology Reports*, **2000**, 2, 182-91	6.3	5
15	Control of nosocomial Clostridium difficile transmission in bone marrow transplant patients. *Infection Control and Hospital Epidemiology*, **2000**, 21, 226-8	2	15
14	Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. *Leukemia and Lymphoma*, **1999**, 32, 279-88	1.9	18

13	Graft-vs.-malignancy with allogeneic blood stem cell transplantation: a potential primary treatment modality. *Pediatric Transplantation*, **1999**, 3 Suppl 1, 52-8	1.8	9
12	Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases. *Journal of Clinical Apheresis*, **1999**, 14, 45-9	3.2	6
11	Identification of megakaryocyte precursors in peripheral blood stem cell collections from normal donors. *Journal of Clinical Apheresis*, **1998**, 13, 7-15	3.2	9
10	Collection of peripheral blood stem cells from normal donors 60 years of age or older. *British Journal of Haematology*, **1997**, 97, 485-7	4.5	39
9	Use of Leukemic Dendritic Cells for the Generation of Antileukemic Cellular Cytotoxicity Against Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia. *Blood*, **1997**, 89, 1133-1142	2.2	220
8	Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. *British Journal of Haematology*, **1996**, 93, 940-2	4.5	34
7	Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. *British Journal of Haematology*, **1996**, 94, 155-8	4.5	29
6	Peripheral blood progenitor cell transplantation: a replacement for marrow auto- or allografts. *Stem Cells*, **1996**, 14, 185-95	5.8	41
5	Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. *Leukemia and Lymphoma*, **1994**, 15, 85-90	1.9	3
4	Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. *British Journal of Haematology*, **1994**, 88, 72-8	4.5	49
3	Bone marrow transplantation for Hodgkin's disease--recent advances and current issues. *Leukemia and Lymphoma*, **1993**, 10 Suppl, 103-8	1.9	3
2	A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. *British Journal of Haematology*, **1992**, 81, 170-7	4.5	41
1	Inhibition of the □v integrin-TGF-□axis improves natural killer cell function against glioblastoma stem cells		3